DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5b8xkt/pharmapoint) has announced the addition of the "PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023" report to their offering.
Japan has an increasingly aging society, which will act as a significant driver of growth in this market, along with the introduction of novel therapies for both wet and dry AMD. The wAMD drugs, Fovista and abicipar pegol, are expected to enter the Japanese AMD market in 2019 and 2023, respectively, while the dAMD drugs, lampalizumab and emixustat, are both expected to enter in 2018.
- Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Macular Edema and Macular Degeneration market.
Key Topics Covered:
1. Tables & Figures
3 Disease Overview
3.1 Macular Degeneration Overview
3.2 Macular Edema Overview
4 Disease Management
4.1 Diagnosis and Treatment Overview
5 Competitive Assessment
5.2 Product Profiles - Major Brands
5.2.1 Lucentis (ranibizumab)
5.2.2 Eylea (aflibercept)
5.2.3 Avastin (bevacizumab)
5.2.4 Macugen (pegaptanib sodium)
5.2.5 Visudyne (verteporfin)
6 Unmet Need and Opportunity
6.2 Treatment for Dry AMD
6.3 Longer-Acting Anti-VEGF Drug Therapy
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD
6.5 Less Invasive Drug Formulations
6.6 Awareness and Earlier Patient Diagnosis
6.7 Home Monitoring of AMD Progression
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.2.1 Abicipar pegol
7.3 Promising Drugs in Early-Stage Development
7.4 Other Drugs in Development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/5b8xkt/pharmapoint